

CTAD 2011

Clinical Trials on Alzheimer's Disease

Montpellier '08 | Las Vegas '09 | Toulouse '10 | San Diego '11

Clinical Trials on Alzheimer's Disease

November 3-5, 2011

US Grant Hotel San Diego, CA

<http://www.ctad.fr>



**CTAD
San Diego
2011**



European Alzheimer's Disease Consortium
Montpellier and Toulouse EADC Centers



UC San Diego
SCHOOL OF MEDICINE

Dear Colleague,

After the huge success of our 3rd edition of CTAD 2010 last November in Toulouse, France, we are proud to present our exciting final program for this 4th edition of Clinical Trials on Alzheimer's Disease sponsored by the UC San Diego School of Medicine.

This year's CTAD in San Diego, USA will once again bring the current leaders involved in clinical trials to appreciate the full spectrum of AD from an asymptomatic stage through dementia, discuss the development of the next generation of Alzheimer's disease treatments as well as learn to harmonize the various neuroimaging techniques and their analyses.

Alzheimer's disease is one of the most important health challenges worldwide. This conference will also focus on new results, actual and future methodological issues, disease-modifying outcomes, biomarkers, fundamental research, new therapeutics and impact on the Healthcare economy.

CTAD is the perfect opportunity to hear about the clinical experiences of international teams, exchange with your peers on the difficulties and challenges of Alzheimer's disease and take home some hands-on therapeutic and methodological tools to improve and reinforce your AD clinical trials teams.

Looking forward to seeing you in San Diego!

Paul Aisen - Jacques Touchon - Bruno Vellas - Michael Weiner

SCIENTIFIC COMMITTEE

Paul AISEN (San Diego)
 Kaj BLENNOW (Molndal)
 Merce BOADA (Barcelona)
 Maria CARRILLO (Chicago)
 Mory John DE LEON (New York)
 Bruno DUBOIS (Paris)
 Howard FELDMAN (Vancouver)
 Giovanni B. FRISONI (Brescia)
 Lutz FROELICH (Mannheim)
 Serge GAUTHIER (Montreal)
 Ezio GIACOBINI (Geneva)
 Michael GRUNDMAN (San Diego)
 Harald HAMPEL (Munich)
 Takeshi IWATSUBO (Tokyo)
 Zaven KHACHATURIAN (Washington DC)
 Virginia LEE (Philadelphia)
 Jean-Marc ORGOGOZO (Bordeaux)
 Ronald PETERSEN (Minnesota)
 Lon SCHNEIDER (Los Angeles)
 Eric SIEMERS (Philadelphia)
 Peter SNYDER (Rhode Island)
 Yaakov STERN (New York)
 Jacques TOUCHON (Montpellier)
 John TROJANOWSKI (Philadelphia)
 Bruno VELLAS (Toulouse)
 Michael W. WEINER (San Francisco)
 Gordon WILCOCK (Oxford)
 Bengt WINBLAD (Stockholm)

ORGANIZING COMMITTEE

Paul AISEN
 Jacques TOUCHON
 Bruno VELLAS
 Michael WEINER

CONGRESS SECRETARIAT

ANT Congrès

E-mail : ctad@ant-congres.com - Tel : + 33 (0)4 67 10 92 23

CONTENTS

Program	p. 2 - 15
Program at a glance	p. 2 - 3
Thursday, November 3 rd	p. 4 - 7
Friday, November 4 th	p. 8 - 11
Saturday, November 5 th	p. 12 - 14
Posters	p. 15 - 21
Congress Venue	p. 22
Registration & Accommodations	p. 23
Continuing Medical Education	p. 24 - 25
Faculty List	p. 26 - 28
Disclosure summary	p. 29 - 30
Acknowledgments	p. 31

All presentations are held in the Presidential Ballroom

Thursday, November 3rd		Presidential Ballroom
08.00 - 08.15 a.m	WELCOME	
08.15 - 08.45 a.m	OPENING KEYNOTE	
08.45 - 09.45 a.m	Symposium 1 : Neuroscience-based Cognitive Assessments to Detect the Preclinical Phase of Alzheimer's Disease	
09.45 - 10.45 a.m	Symposium 2 : The Alzheimer's Prevention Initiative: Overview and Progress	
	<i>Coffee Break and poster sessions</i>	Celestial Ballroom
11.15 - 12.15 p.m	ORAL COMMUNICATIONS	
	<i>Lunch break and poster sessions</i>	Celestial Ballroom
01.15 - 02.15 p.m	Symposium 3 : Improving Measurement Methodology To Detect Treatment Effect In Clinical Trials	
02.15 - 03.30 p.m	ORAL COMMUNICATIONS	
	<i>Coffee Break and poster sessions</i>	Celestial Ballroom
04.00 - 05.30 p.m	ORAL COMMUNICATIONS	
05.30 - 06.00 p.m	CLOSING KEYNOTE	
06.15 p.m	Bus departure to the reception	
06.15 - 09.00 p.m	WELCOME RECEPTION OFFSITE	

Friday, November 4 th		Presidential Ballroom
08.30 - 09.45 a.m	Symposium 4 : Event-Related Potential Biomarkers for Early Diagnosis and Treatment Trials of Alzheimer's Disease	
09.45 - 10.30 a.m	ORAL COMMUNICATIONS	
	<i>Coffee Break and poster sessions</i>	Celestial Ballroom
11.00 - 12.00 p.m	Symposium 5 : Are the new AD diagnostic criteria helpful in clinical trials?	
12.00 - 01.00 p.m	ORAL COMMUNICATIONS	
	<i>Lunch break and poster sessions</i>	Celestial Ballroom
02.00 - 03.30 p.m	ORAL COMMUNICATIONS	
03.30 - 04.30 p.m	Symposium 6 : Conversion from MCI to dementia: the weight, quality and reliability of the evidence	
	<i>Coffee Break and poster sessions</i>	Celestial Ballroom
05.00 - 06.00 p.m	Symposium 7 : Measuring the Earliest Symptoms of Mild Cognitive Impairment	
Saturday, November 5 th		
	Presidential Ballroom AB	Presidential Ballroom CD
08.00 - 12.00 p.m	8.00 - 10.00 a.m Focus session : Clinical Trials in Frontotemporal Degeneration and Related Disorders	8.00 - 9.00 a.m Symposium 8 : Novel Conceptual Models of Dementia (NCMD)
		9.00 - 10.00 a.m ORAL COMMUNICATIONS
	<i>Coffee Break and poster sessions</i>	Celestial Ballroom
10.30 - 12.00 p.m	10.30 - 12.00 p.m Focus session : <i>Continued</i>	10.30 -11.30 a.m Symposium 9 : Amyloid-Related Imaging Abnormalities in Amyloid-Modifying Therapy Research
		11.30 - 12.00 p.m ORAL COMMUNICATIONS

Thursday, November 3rd

Presidential Ballroom

08.00 - 08.15 a.m | WELCOME

08.15 - 08.45 a.m | **OPENING KEYNOTE** : The evolution of AD trials*P.Aisen, ADCS, UC San Diego, USA*08.45 - 09.45 a.m | **Symposium 1** : Neuroscience-based Cognitive Assessments to Detect the Preclinical Phase of Alzheimer's Disease

- Eyeblink Classical Conditioning: A Model System-Based Measure for the Early Detection of Alzheimer's Disease
- Translational Assessment of Memory for the Early Identification of Cognitive Impairment
- A Scalable Unobtrusive Home-Based Monitoring System to Assess Everyday Functional Ability Prior to Mild Cognitive Impairment

Chair : *D.Woodruff-Pak, Temple University, Philadelphia, USA***Speakers** : *J.Raber, J.Kaye, Oregon Health Science University, USA*09.45 - 10.45 a.m | **Symposium 2** : The Alzheimer's Prevention Initiative: Overview and Progress*P.Tariot, J.Langbaum, A.Fleisher, Banner Alzheimer's Institute, Phoenix, USA*10.45 - 11.15 a.m | *Coffee Break and poster sessions*

Celestial Ballroom

11.15 - 12.15 p.m | **ORAL COMMUNICATIONS***Moderators* : *R.Spiegel, Basel University Hospital, CH, J.Touchon, Montpellier University Hospital, FR*11.15 - 11.30 a.m | **O1** - Optimizing The ADAS-Cog For MCI And Early AD*N.Raghavan, PhD, Johnson and Johnson, USA**M.N.Samtani, PhD, M.Farnum, PhD, E.Yang, PhD, V.Lobanov, PhD, G.Novak, MD, V.Narayan, PhD, A.DiBernardo, MD*11.30 - 11.45 a.m | **O2** - Plasma amyloid β concentrations and prognosis in incident dementia cases: the prospective Three-City Study*A.Gabelle, Montpellier University Hospital, France**F.Richard, La.Gutierrez, S.Schraen-Maschke, Jf.Dartigues, C.Tzourio, A.Alperovitch, K.Ritchie, L.Buee, P.Amouyel, J.Touchon, Jc.Lambert, C.Berr*11.45 - 12.00 p.m | **O3** - Bayesian data mining with ensemble learning predicts the conversion from mild cognitive impairment to Alzheimer's disease*R.Chen⁽¹⁾, K.Young⁽²⁾, L.L.Chao⁽²⁾, B.Miller⁽²⁾, K.Yaffe⁽²⁾, M.W.Weiner⁽²⁾, E.H.Herskovits⁽¹⁾**⁽¹⁾ Department of Radiology, University of Pennsylvania, Philadelphia, PA. ⁽²⁾ Center for Imaging of Neurodegenerative Diseases, UCSF VA Medical Center, San Francisco, CA*

12.00 - 12.15 p.m

04 - Validation of the Placebo Group Simulation Approach (PGSA) Using a Large NACC Data Set

R.Spiegel, *Basel University Hospital, Switzerland*
M.Berres, A.R.Miserez, A.U.Monsch

12.15 - 01.15 p.m

Lunch break and poster sessions

Celestial Ballroom

01.15 - 02.15 p.m

Symposium 3 : Improving Measurement Methodology To Detect Treatment Effect In Clinical Trials

- Generative Cognitive Processing Modeling Methods to Measure Treatment Effect
- Use of a subset of the ADAS-cog and MMSE items substantially improves the sensitivity to decline in Mild AD and MCI patients
- Area under the curve analysis to compare treatment group differences: Actual vs. Modeled Results

Chair : *W.Shankle, Medical Care Corporation, Newport Beach, USA*

Speakers : *A.Atri, Massachusetts General Hospital, Boston, USA, S.Hendrix, Pentara Corporation, Salt Lake City, USA*

02.15 - 03.30 p.m

ORAL COMMUNICATIONS

Moderators : C.Sampaio, Faculty of Medicine, Lisbon, Portugal, D.Galasko, University of California, San Diego USA

02.15 - 02.30 p.m

05 - NILVAD: An investigator driven European multi-centre placebo-controlled phase III trial of NILVADIPINE, a calcium channel blocker, in mild to moderate Alzheimer's disease

B.Lawlor, *St. James's Hospital, Dublin, Ireland*
R.A.Kenny, S.Gaynor, M.Mullan, F.Crawford, F.Pasquier, M.Riepe, A.Borjesson, M.Olde-Rickert, R.Howard, D.W.Molloy, J.Kalman, M.Tsolaki, U.Lucca

02.30 - 02.45 p.m

06 - Meta-analysis of composite endpoints in clinical trials of Alzheimer's disease

M.Riepe, *Charité Medical University, Berlin, Germany*
D.Wilkinson, H.Furssl, A.Brieden

02.45 - 03.00 p.m

07 - A Randomized Controlled Alzheimer's disease Prevention Trials Evolution into an Exposure Trial

R.J.Kryscio ^(1,2), E.L.Abner ⁽¹⁾, M.Mendiondo ^(1,2), A.Caban-Holt ⁽³⁾, B.C.Dennis ⁽⁴⁾, C.R.Runyons, F.A.Schmitt ^(3,5), J.J.Crowley ⁽⁶⁾ for the SELECT Investigators

⁽¹⁾ Sanders-Brown Center on Aging, and Departments of Biostatistics, ⁽²⁾ Statistics, ⁽³⁾ Behavioral Science, ⁽⁴⁾ Neurology and Psychiatry, ⁽⁵⁾ Psychology, University of Kentucky, Lexington KY, USA, and Cancer Research and Biostatistics6, Seattle WA, USA

03.00 - 03.15 p.m

08 - Efficacy of a Nutraceutical Formulation on Cognitive Performance and Function in Persons with Mild Cognitive Impairment and Alzheimer's Disease

R.Remington ⁽¹⁾, PhD, C.Bechtel ⁽²⁾, J.Jay Lortie ⁽³⁾, L.Dosanjh ⁽⁴⁾, P.Fishman ⁽⁴⁾, A.Samar ⁽⁵⁾, T.B.Shea ⁽¹⁾

⁽¹⁾ University of Massachusetts Lowell, USA ; ⁽²⁾ Framingham State Univ. ; ⁽³⁾ Heather Hoffmann (Knox College) ; ⁽⁴⁾ Univ of Maryland ; ⁽⁵⁾ Worcester State Univ

Thursday, November 3rd *Continued*

Residential Ballroom

03.15 - 03.30 p.m

O9 - The efficacy of donepezil on a structural outcome (hippocampal atrophy) in the recently defined prodromal Alzheimer's disease (AD) population characterized by a progressive amnesic syndrome of the hippocampal type

B.Dubois⁽¹⁾, M.Chupin⁽²⁾, B.Croisile⁽³⁾, G.Louis Tisserand⁽³⁾, J.Touchon⁽⁴⁾, A.Bonafe⁽⁴⁾, P.J.Ousset⁽⁵⁾, A.Ameur⁽⁶⁾, O.Rouaud⁽⁷⁾, F.Ricolfi⁽⁷⁾, A.Vighetto⁽⁸⁾, F.Pasquier⁽⁸⁾, C.Delmaire⁽⁹⁾, M.Ceccaldi⁽¹⁰⁾, N.Girard⁽¹⁰⁾, S.Lehericy⁽¹¹⁾, I.Tonelli⁽¹²⁾, F.Duveau⁽¹²⁾, L.Garnero⁽²⁾, M.Sarazin⁽¹⁾, D.Dormont⁽²⁾ And The Donepezil Hippocampus Study Group

⁽¹⁾ Institut de la mémoire et de la maladie d'Alzheimer (IMMA) Hopital de la Salpêtrière, Paris, France ; ⁽²⁾ Cognitive Neuroscience and Brain Imaging Laboratory, CNRS UPR640, Paris, France ; ⁽³⁾ Hopital Neurologique Pierre Wertheimer, Lyon, France ; ⁽⁴⁾ CHU, Guy de Chauliac, Montpellier, France ; ⁽⁵⁾ Hopital Casselardit, Toulouse, France ; ⁽⁶⁾ Clinique Pasteur, Toulouse, France ; ⁽⁷⁾ Hôpital général, Dijon, France ; ⁽⁸⁾ CHRU, clinique de Neurologie, Lille, France ; ⁽⁹⁾ Hôpital Roger Salengro, Lille, France ; ⁽¹⁰⁾ Hopital de la Timone, Marseille, France ; ⁽¹¹⁾ Inserm U610 and CENIR, Neuroimaging Unit, Paris, France ; ⁽¹²⁾ Eisai SAS, La Defense 2 cedex, France

03.30 - 04.00 p.m

Coffee Break and poster sessions

Celestial Ballroom

04.00 - 05.30 p.m

ORAL COMMUNICATIONS

Moderators : C.Sampaio, Faculty of Medicine, Lisbon, Portugal, D.Galasko, University of California, San Diego USA

04.00 - 04.15 p.m

O10 - Preclinical Behavioral Detection of Alzheimer's Disease

S.Karantzoulis⁽¹⁾, H.Lau⁽¹⁾, C.E.Myers⁽²⁾, R.P.Kesner⁽³⁾, S.De Santi^(4,1), A.Gurnani⁽¹⁾, H.Scharfman^(5,1), S.H.Ferris⁽¹⁾

⁽¹⁾ New York University Langone Medical Center, NY ; ⁽²⁾ DVA New Jersey Health Care System, and Department of Psychology, Rutgers University ; ⁽³⁾ Department of Psychology, University of Utah ; ⁽⁴⁾ Bayer Healthcare Pharmaceuticals, Inc. ; ⁽⁵⁾ Nathan Kline Institute

04.15 - 04.30 p.m

O11 - A pharmacogenetic-assisted clinical trial to assess the delay of cognitive impairment of the Alzheimer's disease type

A.Roses, Duke University, USA

K.A.Welsh-Bohmer, A.M.Saunders, O.A.Makeeva, D.K.Burns, M.W.Lutz, D.G.Crenshaw, C.A.Metz, S.Brannan

04.30 - 04.45 p.m

O12 - A Randomized Clinical Trial of an inhibitor of RAGE-A-beta interactions in patients with mild to moderate AD

D.Galasko, University of California, San Diego USA

C.Van Dyck, M.Sabbagh, Thomas, RT, Aisen, PS, J.Kupiec, J.Bell, for the Alzheimer's Disease Cooperative Study

04.45 - 05.00 p.m

O13 - Data Matters: What Past Experience Can Tell Us about Power Calculations and Analysis Plans for Future Alzheimer Treatment Trials

S.D.Edland, University of California, San Diego USA

M.Colin Ard

Thursday, November 3rd *Continued*

05.00 - 05.15 p.m

LB11 - Cognitive Decline in the Elderly Population of the GuidAge Study – A 5-Year Follow up of Subjects with Memory Complaints. Is it possible to identify subjects at risk for decline

P.J.Ousset ^(1,2,3), S.Andrieu ^(1,2,3,5), H.Mathiex-Fortunet ⁽⁴⁾, P.Garnier ⁽⁴⁾, J.Touchon ⁽⁶⁾, B.Vellas ^(1,2,3)

⁽¹⁾ INSERM U 1027, Toulouse, France ; ⁽²⁾ University of Toulouse III, Toulouse, France ; ⁽³⁾ Gerontopole, Toulouse University Hospital, Toulouse, France ; ⁽⁴⁾ Ipsen, Boulogne, France ; ⁽⁵⁾ Department of Epidemiology and Public Health, Toulouse University Hospital, Toulouse, France ; ⁽⁶⁾ Montpellier University Hospital

05.15 - 05.30 p.m

LB12 - Representations and practices of prevention in elderly populations: investigating acceptance to participate in and adhesion to an intervention study for the prevention of Alzheimer's disease (ACCEPT study)

S.Andrieu ^(1,2,3,4), N.Coley ^(1,2), V.Gardette ^(1,2,3), J.Subra ⁽⁵⁾, S.Oustric ^(1,2,5), G.A.Andrieu ^(1,2,3,4), B.Vellas ^(1,2,3)

⁽¹⁾ INSERM U 1027, Toulouse, France ; ⁽²⁾ University of Toulouse III, Toulouse, France ; ⁽³⁾ Gerontopole, Toulouse University Hospital, Toulouse, France ; ⁽⁴⁾ Department of Epidemiology and Public Health, Toulouse University Hospital, Toulouse, France ; ⁽⁵⁾ Department of Primary Care, Toulouse University Hospital, Toulouse, France

Presidential Ballroom

05.30 - 06.00 p.m

CLOSING KEYNOTE : Pre-Clinical AD: «What Do the Data Show?»

R.Petersen, Mayo Clinic Alzheimer's Disease Research Center, Rochester, MN, USA

06.15 p.m

Buses departure to the reception

06.30 - 09.00 p.m

WELCOME RECEPTION : *Hosted by the Alzheimer's Disease Cooperative Study at the University of California San Diego, CTAD2011 welcomes us to an evening of networking and relaxation overlooking the San Diego Bay.*

Friday, November 4th

Presidential Ballroom

08.30 - 09.45 a.m

Symposium 4 : Event-Related Potential Biomarkers for Early Diagnosis and Treatment Trials of Alzheimer's Disease

Chairs : *L.Schneider, University of Southern California, A.Budson, Boston University, USA*

Speakers :

- Use of ERPs for Clinical Trials of Preclinical AD/MCI/AD, *J.Olichney, UCSB, USA*
- ERPs in Animal Models: Implications for Translational AD Clinical Trials, *S.Leiser, Lundbeck Research USA*
- ERP Biomarkers as Primary Endpoints in an Industry-Sponsored Phase II AD Clinical Trial
M.Segerdahl, AstraZeneca R&D, USA
- Can ERPs predict the progression of MCI patients?, *K.Bennys, Montpellier University Hospital, France*

09.45 - 10.30 a.m

ORAL COMMUNICATIONS

Moderators : B.Vellas, Toulouse University Hospital, France, P.Schelkens, Alzheimer Centrum, The Netherlands

09.45 - 10.00 a.m

LB1 - MRI Features of Asymptomatic Amyloid Related Imaging Abnormalities-Edema (ARIA-E)

Identified at Baseline in AD Study Cohorts, and MR Artifacts Which Mimic ARIA-E

J.Barakos, MD ^(1,2), C.Carlson, PhD ⁽³⁾, W.Estergard, PharmD ⁽³⁾, J.Oh, PhD ⁽¹⁾, J.Suh, PhD ⁽¹⁾, C.Jack, MD ⁽⁴⁾, E.Siemers, MD ⁽³⁾

⁽¹⁾ Synarc, San Francisco, CA ; ⁽²⁾ California Pacific Medical Center, San Francisco, CA ; ⁽³⁾ Lilly Research Laboratories, Indianapolis, IN ; ⁽⁴⁾ Mayo Clinic, Rochester, MN

10.00 - 10.15 a.m

LB2 - Influence of CSF biomarkers on cognitive decline in an interrupted MCI-trial

O.Peters ⁽¹⁾, L.Katharina Joachim ⁽¹⁾, K.Schmidtke ⁽²⁾, M.Hüll ⁽²⁾, E.Rüther ⁽³⁾, S.Teipel ⁽⁴⁾, H.J.Möller ⁽⁴⁾, F.Jessen ⁽⁵⁾, W.Maier ⁽⁵⁾, J.Kornhuber ⁽⁶⁾, C.Luckhaus ⁽⁷⁾, L.Frölich ⁽⁸⁾, I.Heuser ⁽¹⁾

⁽¹⁾ Department of Psychiatry, Charité - CBF, Berlin ; ⁽²⁾ Center for Geriatric Medicine and Gerontology, University Hospital Freiburg ; ⁽³⁾ Department of Psychiatry, University Göttingen ; ⁽⁴⁾ Department of Psychiatry, Ludwig Maximilian University Munich ; ⁽⁵⁾ Department of Psychiatry, University Bonn ; ⁽⁶⁾ Department of Psychiatry, University Erlangen ; ⁽⁷⁾ Department of Psychiatry, University Düsseldorf ; ⁽⁸⁾ Central Institute of Mental Health, Mannheim

10.15 - 10.30 a.m

LB3 - Title to be announced

P.Schelkens, Alzheimer Centrum, The Netherlands

10.30 - 11.00 a.m

Coffee Break and poster sessions

Celestial Ballroom

11.00 - 12.00 p.m

Symposium 5 : Are the new AD diagnostic criteria helpful in clinical trials?

- Why do we need new criteria?
- Clinical criteria for MCI, AD type
- Imaging Criteria
- Are CSF criteria helpful?

Chairs : *A.Korczyn*, Tel Aviv University Medical School, Israel, *L.Schneider*, University of Southern California, USA, *R.Sperling*, Brigham and Women's Hospital, Massachusetts General Hospital, Boston, USA

12.00 - 01.00 p.m

ORAL COMMUNICATIONS

Moderators : R.McShane, University of Oxford, UK, *M.Grundman*, UC San Diego, USA

12.00 - 12.15 p.m

O14 - Identifying Middle-aged Adults for Participation in AD Prevention Trials Using Dementia Risk Scores vs. Cerebrospinal Fluid Biomarker Cutoffs

C.Carlsson, University of Wisconsin, USA

C.E.Gleason, *S.C.Johnson*, *H.M.Blazel*, *J.H.Barnett*, *N.Martiza Dowling*, *B.P.Hermann*, *A.J.Marsh*, *M.A.Sager*, *H.Zetterberg*, *K.Blennow*, *L.Puglielli*, *C.S.Atwood*, *S.Asthana*

12.15 - 12.30 p.m

O15 - Amyloid deposition and white matter lesions in cognitively healthy elderly

L.Glodzik, NY University Medical Center, USA

H.Rusinek, *L.Mosconi*, *Y.Li*, *E.Pirraglia*, *M.Cummings*, *J.Murray*, *S.Williams*, *C.Randall*, *S.Vallabhajolusa*, *M.de Leon*

12.30 - 12.45 p.m

O16 - Application of Item-Response Theory (IRT) to the Detection of Treatment Effects on Functional Outcomes in Alzheimer's Disease

C.Ard, University of California, San Diego

S.D.Edland Ph.D

12.45 - 01.00 p.m

O17 - Responders to ELND005 (Scyllo-inositol) in an Alzheimer's Disease Study of 78 Weeks Duration: Analysis of their Clinical, v-MRI, and CSF Biomarker Characteristics

A.Porsteinsson ⁽¹⁾ MD, *R.Sperling* ⁽²⁾ MD, *S.Salloway* ⁽³⁾ MD, *G.Crans* ⁽⁴⁾ PhD, *C.Hernandez* ⁽⁴⁾ PhD, *S.Abushakra* ⁽⁴⁾ MD

⁽¹⁾ University of Rochester Medical Center, Rochester NY, ⁽²⁾ Brigham and Women's Hospital, Boston MA, ⁽³⁾ Butler Hospital/Brown University, Providence RI, ⁽⁴⁾ Elan Pharmaceuticals, S. San Francisco

01.00 -02.00 p.m

Lunch Break and poster sessions

Celestial Ballroom

Friday, November 4th *Continued*

02.00 - 03.30 p.m

ORAL COMMUNICATIONS

Moderators : *P.Aisen, UC San Diego, USA, M.Sano, Mount Sinai School of Medicine, NYC, USA*

02.00 - 02.15 p.m

O18 - A 78-week Phase 2 Study of ELND005 (Scyllo-inositol) in Alzheimer's Disease: Clinical Outcomes by Various MMSE Definitions of Mild Disease

S.Salloway ⁽¹⁾ MD, A.Porsteinsson ⁽²⁾ MD, G.Crans ⁽³⁾ PhD, C.Hernandez ⁽³⁾ PhD, S.Abushakra ⁽³⁾ MD
(¹) Butler Hospital/Brown University, Providence RI, (²) University of Rochester Medical Center, Rochester NY, (³) Elan Pharmaceuticals, S. San Francisco

02.15 - 02.30 p.m

O19 - Amyloid Burden and Neuropsychological Test Performance in Cognitively Normal First-Degree Relatives at Varying Genetic Risk for Alzheimer's Disease

C.Van Dyck, A.Bruck, N.M.Barcelos, B.Planeta-Wilson, A.L.Benincasa, M.G.MacAvoy, Y.S.Ding, J.Gelernter, R.E.Carson,
Yale University School of Medicine

02.30 - 02.45 p.m

O20 - Strategies of Enrichment and Stratification for Efficient Alzheimer Disease Clinical Trials Using Longitudinal Structural MRI Outcome Measures

D.Holland, *University of California, San Diego, USA*
L.K.McEvoy, A.M.Dale

02.45 - 03.00 p.m

O21 - Targeting vascular activation: a novel therapeutic strategy for Alzheimer's disease

P.Grammas, *Texas Tech University Health Science Center, USA*
L.Yin, A.Sanchez, M.Evola, A.Young, *Garrison Institute on Aging, Texas Tech University Health Science Center, Lubbock, TX*

03.00 - 03.15 p.m

O22 - Disease-modification in MCI with homocysteine-lowering B vitamins slows atrophy of particular brain regions: the VITACOG trial

G.Douaud ⁽¹⁾, H.Refsum ⁽²⁾, C.A.de Jager ⁽²⁾, K.Bradley ⁽²⁾, R.Jacoby ⁽²⁾, S.M.Smith ⁽¹⁾, A.D.Smith ⁽²⁾
(¹) FMRIB Centre, University of Oxford, Oxford, UK, (²) OPTIMA, University of Oxford, Oxford, UK

03.15 - 03.30 p.m

LB4 - AFFITOPE® Alzheimer vaccines – Results from clinical phase I support the further clinical development of AFFITOPE® AD02

A.Schneeberger, M.Mandler, F.Mattner, W.Schmidt, *AFFIRIS AG, Vienna, Austria*

Friday, November 4th *Continued*

Presidential Ballroom

03.30 - 04.30 p.m

Symposium 6 : Conversion from MCI to dementia: the weight, quality and reliability of the evidence

Chair : *R.McShane, Cochrane Dementia and Cognitive Improvement Group, University of Oxford, UK*

- Systematic review of longitudinal studies of amyloid PET ligands
N.Smailagic, CDCIG, University of Cambridge, UK
- Reporting standards in diagnostic test accuracy studies in the dementia literature: a review and recommendations
A.Noel-Storr, CDCIG, University of Cambridge, UK
- Reliability of the “dementia outcome”: what can we learn from Stroke?
T.Quinn, CDCIG, University of Oxford, UK

04.30 - 05.00 p.m

Coffee Break and poster sessions

Celestial Ballroom

05.00 - 06.00 p.m

Symposium 7 : Measuring the Earliest Symptoms of Mild Cognitive Impairment

- The Signal from Trials: Perceived Deficits
- Industry Partnerships in Pre-Competitive Measure Development in MCI
- Findings from the Cognition Working Group of the PRO Consortium

Chair : *D.Miller, L.Frank, United BioSource Corporation, USA*

Speakers : *R.Doody, Baylor College of Medicine, C.Leibman, Janssen Alzheimer Immunotherapy, USA*
W.Lenderking, United BioSource Corporation, USA

Saturday, November 5th

Presidential Ballroom AB

08.00 - 12.00 p.m

Focus session (8.00 a.m - Noon) : Clinical Trials in Frontotemporal Degeneration and Related Disorders

Chair : *A.Boxer, University of California, San Francisco, USA*

Speakers : *A.Boxer⁽¹⁾, J.Cummings⁽²⁾, M.Gold⁽³⁾, H.Feldman⁽⁴⁾, D.Knopman⁽⁵⁾, I.Mackenzie⁽⁶⁾, T.Huey⁽⁷⁾,*

H.Rosen⁽¹⁾, J.Kramer⁽¹⁾, W.Hu⁽⁸⁾

⁽¹⁾ *University of California, San Francisco*

⁽²⁾ *Cleveland Clinic Lou Ruvo Brain Institute*

⁽³⁾ *Allon Therapeutics*

⁽⁴⁾ *Bristol Myers Squibb*

⁽⁵⁾ *Mayo Clinic, Rochester*

⁽⁶⁾ *University of British Columbia*

⁽⁷⁾ *Columbia University*

⁽⁸⁾ *Emory University*

Presidential Ballroom CD

08.00 - 09.00 a.m

Symposium 8 :
Novel Conceptual Models of Dementia (NCMD)
Z.Khachaturian, PAD2020 Potomac, USA

ORAL COMMUNICATIONS

Moderator : P.J.Ousset, Toulouse University Hospital, France

09.00 - 09.15 a.m

LB5 - A multi-center, randomized, double-blind, placebo-controlled trial of vitamin E in aging persons with Down syndrome

M.Sano, *Mount Sinai School of Medicine, USA*

A.Dalton, PhD, P.Aisen, MD, W.Y.Tsai, PhD, H.Andrews, PhD

09.15 - 09.30 a.m

LB6 - Tesamorelin, a growth hormone-releasing hormone analogue, improves cognitive function in MCI and healthy aging: results of a randomized controlled trial

L.Baker, *VAPSHCS, Seattle, USA*

S.M.Barsness, S.Borson, G.R.Merriam, S.D.Friedman, S.Craft, M.V.Vitiello

Saturday, November 5th *Continued*

Presidential Ballroom AB	Presidential Ballroom CD
<p>Focus session <i>continues</i></p>	<p>09.30 - 09.45 a.m LB7 - Phase II clinical trial of metformin in amnesic MCI: rationale, methods, and barriers and enablers of successful recruitment T.Perez, MD, S.Thareja, E.Arana, H.Chang, E.Bagiela, PhD, <u>J.A.Luchsinger</u>, MD MPH <i>Columbia University Medical Center, New York, NY</i></p> <p>09.45 - 10.00 a.m LB8 - The Effects of ELND005 (Scyllo-inositol) on Emergence of New Neuropsychiatric Symptoms in a 78-Week Phase 2 Study in Mild and Moderate Alzheimer's Disease <u>C.Lyketsos</u>, <i>The Johns Hopkins Bayview Medical Center, Baltimore, USA</i> S.Abushakra MD, P.Tariot MD, G.Crans PhD, C.Hernandez PhD, J.Cedarbaum MD</p>
<p>10.00 - 10.30 a.m <i>Coffee Break and poster sessions</i></p>	<p>Celestial Ballroom</p>

10.00 - 10.30 a.m

Coffee Break and poster sessions

Celestial Ballroom

Presidential Ballroom AB	Presidential Ballroom CD
<p>10.30 - 12.00 p.m</p> <p>Focus session : Clinical Trials in Frontotemporal Degeneration and Related Disorders <i>Continued</i></p>	<p>10.30 - 11.30 a.m</p> <p>Symposium 9 : Amyloid-Related Imaging Abnormalities in Amyloid-Modifying Therapy Research</p> <ul style="list-style-type: none"> Targeting beta-amyloid in the brain <i>Chair : J.Touchon, Montpellier University Hospital, France</i> Alzheimer's Association Research Roundtable recommendations on ARIA in Amyloid Modifying Therapeutic Trials Clinical: perspective and recommendations <i>M.Carrillo, Alzheimer's Association, Chicago, IL, USA</i> Understanding the pathophysiology of ARIA <i>S.Salloway, Butler Hospital, RI, USA</i> Overview of experimental evidence and insights from nonclinical data <i>G.Kinney, Janssen AI San Francisco, CA, USA</i> <p>ORAL COMMUNICATIONS</p> <p><i>Moderators : Z.Khachaturian, PAD2020 Potomac, USA</i></p> <p>11.30 - 11.45 p.m</p> <p>LB9 - Responder Analyses from a Phase 2 Placebo-Controlled Study of ELND005 (Scyllo-inositol) in Mild and Moderate Alzheimer's Disease <u>A.Porsteinsson</u> ⁽¹⁾ MD, R.Sperling ⁽²⁾ MD, G.Crans ⁽³⁾ PhD, C.Hernandez ⁽³⁾ PhD, S.Abushakra ⁽³⁾ MD <i>(1) University of Rochester Medical Center, Rochester NY, (2) Brigham and Women's Hospital, Boston MA, (3) Elan Pharmaceuticals, S.San Francisco</i></p> <p>11.45 - 12.00 p.m</p> <p>LB10 - Towards retinoid therapy for Alzheimer's disease <u>K.Shudo</u>, <i>Itsuu Laboratory, Tokyo, Japan</i> H.Fukasawa, M.Nakagomi, N.Yamagata, Y.Amano, T.Miki</p>

SCIENTIFIC POSTERS

They will be displayed all day long in the Celestial Ballroom during the entire event.
You will get a chance to meet with their authors during coffee breaks and lunches taking place in the Celestial Ballroom.

For your convenience posters are classified by themes and numbered accordingly :

THEMES		
Biomarkers AD/Imaging	P1 through P13	p.16 to 17
Clinical trials assessment tools	P14 through P20	p.17 to 18
Clinical trials methodology	P21 through P29	p.18 to 19
Treatment therapeutics for AD	P30 through P38	p.19 to 20
Fundamental research in AD	P39 and P40	p.20
Nutrition	P41 and P42	p.20
Miscellaneous	P43 and P44	p.21

POSTERS

Celestial Ballroom

Biomarkers AD/Imaging

- P1** Brain Metabolite Changes in Mild and Moderate Alzheimer's Disease : Correlation with v-MRI and Clinical Measures of Disease Severity
S.Abushakra
Co-authors : *G.Crans PhD, S.Narayanan PhD, E.Liang PhD, C.Hernandez PhD, D.Arnold MD*
- P2** The Scopolamine model, cognitive p300 potentials and quantitative EEG : from region-specific targets to biomarker of drug efficacy
P.Boeijinga
Co-authors : *N.Pross, P. Danjou, L.Soufflet, E.Voltz, R.Barnouin*
- P3** The importance of S1-pocket of glutamate carboxypeptidase II in exerting Amyloid beta degradation activity
K.Hyunyoung Kim
Co-authors : *S.Kyung Lee, M.J.Kim, S.Ick Park*
Division of Brain Disease, Korea National Institute of Health, South Korea
- P4** Event-Related Potential (ERP) & Quantitative Electroencephalography (qEEG) Biomarkers for Alzheimer's Disease : The COGNISION™ System
M.Kulkarni (1)
Co-authors : *M.Cecchi (1), D.A.Casey (2), G.A.Jicha (3), P.R.Solomon (4), P.M.Doraiswamy (5), D.A.Wolk (6), S.E.Arnold (6), C.D.Smith (3)*
(1) *Neuronetrix*; (2) *University of Louisville, KY*; (3) *University of Kentucky, KY*; (4) *The Memory Clinic, VT*; (5) *Duke University*; (6) *University of Pennsylvania*
- P5** Differences among Protocols for Manual Hippocampal Segmentation : Preparatory Steps to an EADC-ADNI Delphi Panel for the Development of a Harmonized Protocol
G.Frisoni
Co-authors : *M.Boccardi, M.Bocchetta, R.Ganzola, N.Robitaille, A.Redolfi, G.Bartzokis, R.Camicoli, J.G.Csernansky, M.J.de Leon, L.deToledo-Morrell, R.J.Killiany, S.Lehéricy, J.Pantel, J.C.Pruessner, H.Soininen, C.Watson, S.Duchesne, C.R.Jack*
- P6** Cut-off of the CSF biomarkers for AD diagnosis in French memory centers
A.Gabelle
Co-authors : *J.Dumurgier, O.Vercruysee, C.Paquet, S.Bombois, J.Hugon, C.Chaulet, F.Pasquier, J.Touchon, J.L.Laplanche, S.Schraen, S.Lehmann*
- P7** Dynamic Bayesian network modeling reveals altered trajectory interaction between hippocampus and the entorhinal cortex in mild cognitive impairment
E.Herskovits
Co-authors : *R.Chen and the Alzheimer's Disease Neuroimaging Initiative*
Department of Radiology, University of Pennsylvania, Philadelphia, PA
- P8** Noninvasive assessment of drug binding site with positron emission tomography is useful in the prediction of the efficacy of cholinesterase inhibitor
N.Okamura
Co-authors : *M.Kasuya, H.Ishikawa, N.Tanaka, Y.Funaki, R.Iwata, K.Meguro, K.Yanai*
- P9** Alzheimer's disease biology of a 96 gene expression assay developed to aid in the diagnosis of the disease
A.Lonneborg
Co-authors : *G.Grave, H.M.Andersen, L.Kristiansen, T.Lindahl, L.Roed, P.Sharma*
- P10** Development of a blood-based gene expression test to identify prodromal Alzheimer's disease
A.Lonneborg
Co-authors : *L.Roed, G.Grave, T.Lindahl, E.Rian, A.K.Knutsen, P.Sharma*

- P11** Clinical longitudinal study of inflammatory factors in plasma and PBMCs of patients with Alzheimer's disease : predictive value of cytokines
A.Julian (1)
 Co-authors : *G.Page (1), T.Dantoine (5), P.Krolak-Salmon (6), G.Berrut (7), C.Hommet (8), O.Beauchet (9), O.Hanon (10), L.Blanchard (3), S.Brishoual (3), S.Ragot (3), M.Paccallin (1,2,3,4)*
 (1) Research Group on Brain Aging, EA 3808, University of Poitiers; Department of Geriatrics ; (2) University Hospital Poitiers ; (3) Centre d'Investigation Clinique INSERM 802; Research and Resource Memory Centers ; (4) Poitiers ; (5) Limoges ; (6) Lyon ; (7) Nantes ; (8) Tours ; (9) Angers ; (10) Broca Paris, France
- P12** The Beta-amyloid pool in blood helps to distinguish between prodromal AD (probable) MCI and other MCI
P.Pesini
 Co-authors : *V.Perez-Grijalba, I.Monleon, M.Boada, L.Tarraga, I.San-José, P.Pesini, M.Sarasa*
- P13** 6-Biomarker algorithms identify Alzheimer's disease at high accuracy
M.Zellner
 Co-authors : *A.Graf, R.Babeluk, M.Veitinger, E.Umlauf*
 Medical University of Vienna, Vienna, Austria

Clinical trials assessment tools

- P14** Age-expanded normative data for the Ruff 2&7 Selective Attention Test; Evaluating selective attention in older individuals for clinical trials
A.Caban-Holt
 Co-authors : *E.Abner, MPH, R.Kryscio, Ph.D., B.Dennis, D.Psy, F.Schmitt, Ph.D*
- P15** Variability in MMSE Scores Between Screening and Baseline Visits in 2 Large, Multi-National Alzheimer's Disease Study Programs: A Concern and Potential Solutions
D.Miller
 Co-authors : *A.Young, MS (United BioSource Corporation, Wayne, PA, US), W.Estergard, PharmD, D.Henley, MD, K.Sundell, BS*
- P16** Use of informant-reported web-based data collection to assess dementia symptoms: validation in relation to the Dependence Scale
K.Rockwood (1)
 Co-authors : *A.Zeng (1), C.Liebman (2), A.Mitnitski (1)*
 (1) DementiaGuide Inc., Halifax, NS Canada
 (2) Janssen Alzheimer Immunotherapeutics PLC, San Francisco, CA, USA
- P17** Comparison of motor performance in upper and lower extremities under dual-task patients with mild Alzheimer's dementia
A.Wong
 Co-authors : *C.Gung Memorial Hospital Taiwan R.O.C, S.W.Chou, MD, PhD, C.W.Wu, MD, C.Chang Huang, MD, M.C.Chiou, MD, H.C.Fung, MD, PhD*
- P18** Framework for Patient Synchronization via ADAS-Cog 13 and its Consequences for Disease Progression Visualization and Clinical Trials
E.Yang
 Co-authors : *M.Farnum, PhD, V.Lobanov, PhD, T.Schultz MS, N.Raghavan, PhD, M.N.Samtani, PhD, G.Novak, MD, V.Narayan, PhD, A.DiBernardo, MD*
- P19** Microarray-based transcriptomic signatures to help improving the success rate of ad Clinical Trials
M.Pando
 Co-authors : *P.Beurdeley, L.Desire, V.Kotraiah, M.Pando, I.Barber*

POSTERS

Clinical trials assessment tools (Continued)

- P20** The Brief Episodic Memory Assessment: A new scale to measure the episodic memory in Alzheimer's disease to complement new one-plus-one in vivo diagnosis strategy
Prophase
 Co-authors : C.Yavorsky, PhD, A.Khan, PhD, A.Defries, MA, M.Opler, MPH, PhD

Clinical trials methodology

- P21** Practice Effects in a Longitudinal, Multi-Center Alzheimer's Disease Prevention Clinical Trial
B.Dennis (1)
 Co-authors : E.L.Abner (2), A.Caban-Holt (4), M.Mendiondo (2,3), R.J.Kryscio (2,3), F.A.Schmitt (1,4,5), J.J.Crowley (6) for the SELECT Investigators
 (1) Sanders-Brown Center on Aging, and Departments of Neurology, (2) Biostatistics, (3) Statistics, (4) Behavioral Science, (5) Psychiatry & Psychology, (6) University of Kentucky, Lexington KY, USA, and Cancer Research and Biostatistics, Seattle WA, USA
- P22** Compliance with the requirements of anti-Alzheimer's with the main recommendations issued in March 2008 HAS
A.Guérin (1)
 Co-authors : L.Joffredo (2), A.Chevallier (1), FX Chedhomme (1)
 (1) Pharmacy unit; (2) Medical unit, Broca hospital, APHP Paris France
- P23** Examining recruitment in a Phase II multisite industry-sponsored interventional trial in mild-to-moderate Alzheimer's disease
J.Grill (1)
 Co-authors : D.Elashoff, PhD (1), J.Hazel RN (2), R.Berman, MD (2), V.Coric, MD (2)
 (1) Mary Easton Center for Alzheimer's disease Research at UCLA, Los Angeles, CA; (2) Bristol-Myers Squibb Research & Development, Wallingford, CT
- P24** Estimating sample sizes for predementia Alzheimer's disease clinical trials based on the Alzheimer's Disease Neuroimaging Initiative
J.Grill (1)
 Co-authors : L.Di, PhD (1,3), D.Elashoff, PhD (1,3), P.H.Lu, PsyD (1), O.Kohannim (2), L.Apostolova, MD (1), J.M.Ringman, MD (1), J.L.Cummings, MD (4), P.Thompson, PhD (2), and the Alzheimer's Disease Neuroimaging Initiative
 (1) Mary Easton Center for Alzheimer's Disease Research; (2) Laboratory of Neuroimaging, Department of Neurology; (3) Department of Medicine Statistics Core, University of California, Los Angeles, David Geffen School of Medicine; (4) Lou Ruvo Institute for Brain Health, Cleveland Clinic, Las Vegas, NV
- P25** What Promising Recruitment Strategies Promote Continued Participation in Alzheimer's Disease Prevention Trials?
L.Jacobson, School of Medicine University of Wisconsin, Madison, WI
 Co-authors : H.M.Blazel, C.E.Gleason, S.C.Johnson, M.A.Sager, K.M.Paterson, S.Asthana, C.M.Carlsson CM
- P26** Protocols from Hell : a review of difficulties in conducting clinical trials in Alzheimers Disease
R.Hogarth
 Co-authors : S.Kurrie MD PhD
 Division of Rehabilitation and Aged Care, Hornsby Ku-ring-gai Hospital Hornsby, Australia
- P27** Statistical Considerations for Designing a Longitudinal Clinical Trial in Early (Prodromal) Alzheimer's Disease Subjects
Y.Peng
 Co-authors : M.Ryan

Clinical trials methodology (Continued)

- P28** Which are the reasons to not include AD patients in clinical trials?
A. Rollin-Sillaire (1,2)
 Co-authors : *L. Breuilh (1,2), N. Jourdan (1, 2), F. Pasquier (1,2)*
 (1) Université Lille Nord de France, UDSL, EA 1046, Lille, France ; (2) Memory Clinic, Lille University Hospital, Lille, France
- P29** Assessing reliability of distributed data entry of the adas-cog in a multicentered Clinical Trial
S. Walters
 Co-authors : *D. Gessert, M. Donohue, PhD., P. Aisen, MD. Alzheimer's Disease Cooperative Study*
 Acknowledgements : *T. Sather, M. Davis, E. J. Trinidad, I. Sim, L. Boullil, W. C. Liu*

Treatment therapeutics for AD

- P30** NPT001: A Novel Therapeutic Approach for Reducing Levels of Both Beta-Amyloid Plaques and Neurofibrillary Tangles in Alzheimer's Disease
R. Fisher (1)
 Co-authors : *S. Kimberley, S. Gannon (1), R. Krishnan (1), H. Tsubery (1), M. Lulu (1), M. Gartner (1), M. Proschitsky (1), M. Becker (5), J. Wright (1), E. Rockenstein (2), El. Masliah (2), D. Kirschner (3), D. Myszyka (4), B. Solomon (5)*
- P31** Impact of initiation of treatment with Memantine or Cholinesterase Inhibitors (ChEI) on the use of Psychotropic Drugs: Analysis of RAMQ Database
J. Lachaine (1)
 Co-authors : *C. Beauchemin (1), A. Crochard (2), S. Bineau (3)*
 (1) Faculty of Pharmacy, University of Montreal, Montreal, Quebec, Canada ; (2) Market Access Department, Lundbeck SAS, Issy-Les-Moulineaux, France ; (3) Global Outcomes Research Division, Lundbeck SAS, Issy-Les-Moulineaux, France
- P32** Combination memantine with acetylcholinesterase inhibitor delays the admission of Alzheimer's disease patients to nursing home: Cost-effectiveness analysis in France
J. Lachaine (2)
 Co-authors : *J. Touchon (1), C. Beauchemin (2), A. Crochard (3), B. Rive (4), S. Bineau (4)*
 (1) Faculty of Medicine, University of Montpellier, France ; (2) Faculty of Pharmacy, University of Montreal, Montreal, Quebec, Canada ; (3) Market Access Department, Lundbeck SAS, Issy-Les-Moulineaux, France ; (4) Global Outcomes Research Division, Lundbeck SAS, Issy-Les-Moulineaux, France
- P33** The tacrine derivative 7-MEOTA in the treatment of AD
O. Soukup (1,2)
 Co-authors : *J. Patocka (4), J. Zdarova-Karasova (1,2), M. Pohanka (1,3), D. Jun (1,3), K. Kuca (1,3)*
 (1) University hospital of Hradec Kralove, Czech Republic ; (2) Department of Toxicology ; (3) Center of Advanced Studies, Faculty of Military Health Sciences, University of Defence, Hradec Kralove, Czech Republic ; (4) Department of Radiology and Toxicology, Faculty of Health and Social Studies, University of South Bohemia Ceske Budejovice, Czech Republic
- P34** A Novel Neurotrophic Drug For Cognitive Enhancement And Alzheimer's Disease
M. Prior
 Co-authors : *Q. Chen, P. Maher, D. Schubert*
- P35** Correlations of Pharmacokinetic (PK) Measures to Pharmacodynamic (PD) Effects of ELND005 (Scyllo-inositol) from a Phase 2 Dose-Ranging Study in Mild to Moderate Alzheimer's Disease
E. Liang
 Co-authors : *J. Wagg, F. Jonsson, J. Cedarbaum, S. Abushakra*

POSTERS

Treatment therapeutics for AD (Continued)

- P36** Effect of Ratanasampil (Tibet-medicine) on changes of serum -amyloid protein and inflammatory markers in patients with mild to moderate Alzheimer's disease
A.Zhu
Co-authors : Y.Chu, X.Zhong, G.Li, B.Liao, J.Zhou, S.Gu, M.Yu
- P37** Etazolate treatment in a genetic model of Alzheimer disease: rescue of cognitive impairments and physiological biomarkers
D.Colas
Co-authors : Y.Kayo, C.Bayara, H.Grace, H.H.Craig
- P38** Title of poster to be announced onsite
R.Shah

Fundamental research on animal models

- P39** Are Transgenic Mice Valid Animal Models for the Search for New Treatments for Alzheimer's Disease (AD)
J.Holtzman
Department of Pharmacology, University of Minnesota, Minneapolis, MN 55455, United States
- P40** Efficacy Study of Lp-PLA2 Inhibitor -859 in the Hypercholesterolemic Rabbit Model of Alzheimer's Disease
D.Woodruff-Pak, Neuroscience Program and Psychology Department, Temple University, Philadelphia, PA - USA
Co-authors : K.L.Brown, D.Comalli, C.Shriver, A.Agelan, D.Pratico, Y.Persidsky, S.H.Ramirez, C.Macphee, C.B.Guan

Nutrition

- P41** The effects of a multi-nutrient drink on functional connectivity in patients with Alzheimer's disease
M.Lansbergen (2)
Co-authors : H.de Waal (1), E.van Straaten (1), P.Scheltens (1), R.L.Wiegers (2), P.J.Kamphuis (2,3), C.J.Stam (1)
(1) Alzheimer Centre, VU University Medical Centre, Department of Neurology, Amsterdam, The Netherlands ; (2) Nutricia Advanced Medical Nutrition, Danone Research - Centre for Specialised Nutrition, Wageningen, The Netherlands ; (3) Utrecht Institute for Pharmaceutical Sciences (UIPS), Utrecht University, Utrecht, The Netherlands
- P42** The LipiDiDiet study: rationale and study design
R.Wiegers
Co-authors : Y.Freund-Levi (1), P.J.Visser (2,3), M.Kivipelto (4), R.L.Wiegers (5), T.Hartmann (6,7), H.Soininen (8)
(1) Department of NVS, Section of Clinical Geriatrics, Karolinska Institutet, Karolinska University Hospital, Huddinge, Sweden ; (2) Department of Psychiatry and Neuropsychology, Alzheimer Center Limburg, University of Maastricht, Netherlands ; (3) Department of Neurology, Alzheimer Center, VU University Medical Center, Amsterdam, Netherlands ; (4) Aging Research Center, Karolinska Institutet and Stockholm Gerontology Research Center, Stockholm, Sweden ; (5) Nutricia Advanced Medical Nutrition, Danone Research, Centre for Specialised Nutrition, Wageningen, The Netherlands ; (6) Deutsches Institut für Demenz-Prevention (DIDP), Neurodegeneration and Neurobiology ; (7) Experimental Neurology, Homburg, Germany ; (8) Department of Neurology, University of Eastern Finland and Kuopio University Hospital, Kuopio, Finland

Miscellaneous

P43 Recognition of Facial Expressions and Emotional Prosody in Alzheimer Disease
H. Costa
 Co-authors : *W.Cristina de Souza*

P44 Relationship between patient dependence on others and resource utilization in Alzheimer's disease (AD): results from a longitudinal study
L.Lacey, Janssen Alzheimer Immunotherapy Dublin - Ireland
 Co-authors : *T.Niecko, C.Leibman, E.Liu, M.Grundman, for the ELN_AIP_901 investigator group*





WELCOME RECEPTION

Hosted by the Alzheimer's Disease Cooperative Study at the University of California San Diego, CTAD2011 welcomes us to an evening of networking and relaxation. Just steps away from Seaport Village, PETCO Park, the famous Gaslamp District and the Convention Center, Roy's San Diego Waterfront provides the most extraordinary waterfront views in the city.

Buses will depart at 6 pm from the US Grant and return attendees directly to the hotel afterwards.

Roy's San Diego Waterfront
333 West Harbor Drive
San Diego, CA 92101

CONGRESS VENUE

THE US GRANT, 326 Broadway San Diego, CA 92101

CtaD 2011 is being held at the US Grant, a San Diego Icon since 1910, the palatial US GRANT hotel is situated in the city's lively and historic downtown Gaslamp Quarter with a dazzling array of dining, shopping, nightlife and entertainment venues for all ages. Explore the city's young heritage and learn about early settlers, including Alonzo Horton and Wyatt Earp at the Gaslamp Quarter Historical Foundation. Your journey can include daytime exploratory tours or an experience within the region's energetic restaurants and nightlife.

The hotel is easily accessible to San Diego International Airport (15 minutes away) and offers close proximity to the San Diego Cruise Ships terminal, Santa Fe Depot Train Station, as well as the I-5 Freeway. Parking is available at the hotel.



REGISTRATION & ACCOMMODATIONS

REGISTRATION AVAILABLE ON LINE : www.ctad.fr

EADC member registration fee (1*)	US\$ 745
Registration fee (1*)	US\$ 850

THERE WILL BE NO REGISTRATIONS ONSITE

(1*) Your registration fees include :

- Admission to the full CtaD 2011 conference with all scientific sessions
- Attendee bag with full-program and JNHA review
- Coffee breaks
- Lunch breaks
- Welcome reception

ACCOMMODATIONS : STAY CLOSE TO THE CONFERENCE VENUE !

The US Grant is now sold out but CTaD has negotiated special rates at the Westin Gaslamp across the street from the US Grant, book your room quickly to be sure to secure a hotel room close to the conference venue.

You can book directly on our website: www.ctad.fr

Continuing Medical Education

Course Description

The development of the next generation of Alzheimer's disease treatments is among the most important health needs worldwide, but presents huge challenges. The goal of the meeting is to bring together today's worldwide leaders in the treatment of Alzheimer's disease to discuss new results, drugs in development, and future methodological issues presented in the development of the next generation of Alzheimer's disease treatments. This year's topics of discussion include preliminary or new results concerning drug discovery, clinical trials of new therapies in development, methodological issues relating to disease modifying treatments, outcome measurements, biomarkers validation, and health economics.

Target Audience

This conference is designed for neurologists, psychiatrists, geriatric and imaging specialists and physicians interested in finding solutions to the difficulties that have slowed the pace of progress, with a particular focus on clinical trial methodology. Other healthcare professionals who may benefit from this activity are clinical research coordinators, nurses, speech therapists and other AD and dementia occupational therapists, psychologists and neuropsychologists.

Course Objectives

Upon completion of this conference, participants should be able to:

1. Appreciate the full spectrum of AD from an asymptomatic stage through dementia
2. Harmonize neuroimaging methods and analysis for incorporation into trials and clinical practice
3. Elucidate the risk factors for AD and other dementias
4. Identify and avoid methodological errors in the design of multicenter and international clinical trials
5. Use improved measurement of cognitive deficits in their practice
6. Better understand the sequence and relationship among the biochemical and neuroimaging biomarkers of AD

Needs Assessment

The development of the next generation of Alzheimer's disease treatments is among the most important health needs worldwide, but presents huge challenges. Despite major advances in understanding the neurobiology of the disease and identifying plausible therapeutic targets, no new drug has been approved for AD treatment since 2003. The slow progress may have as much or more to do with methodological challenges than with the development of specific drug candidates. This conference brings together world leaders in AD treatment to discuss solutions to the difficulties that have slowed the pace of progress, with a particular focus on clinical trial methodology.

The Scientific committee of this conference has identified practice gaps in the following areas related to the design and conduct of AD clinical trials :

- The need to appreciate the full spectrum of AD from an asymptomatic stage through dementia
- The need for harmonization of neuroimaging methods and analysis for incorporation into trials and clinical practice
- The need to elucidate the risk factors for AD and other dementias
- The need to identify and avoid methodological errors in the design of multicenter and international clinical trials
- The need for improved measurement of cognitive deficits
- The need to clarify the sequence and relationship among the biochemical and neuroimaging biomarkers of AD

Beyond the global practice gaps addressed throughout the conference, other in-depth sessions will cover some specific issues related to the following needs/practice gaps :

- The need to evaluate the relevance of new criteria and their relevance



- The need to clarify the issue of Event-Related Potential Biomarkers for Early Diagnosis and Treatment Trials of Alzheimer's Disease
- The need to properly assess the decline in cognitive function, which is the key change heralding the onset of mild cognitive impairment and dementia in Alzheimer's disease (AD)
- The need to clarify the weight, quality and reliability of the evidence in conversion from MCI to dementia in AD
- The need to improve measurement methodology to detect treatment effect in clinical trials

Accreditation Statement

The University of California, San Diego School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement

The University of California, San Diego School of Medicine designates this live activity for a maximum of 18.75 *AMA PRA Category 1 Credits*[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Cultural and Linguistic Competency Statement

California Assembly Bill 1195 requires continuing medical education activities with patient care components to include curriculum in the subjects of cultural and linguistic competency. It is the intent of the bill, which went into effect on July 1, 2006, to encourage physicians and surgeons, CME providers in the state of California, and the Accreditation Council for Continuing Medical Education to meet the cultural and linguistic concerns of a diverse patient population through appropriate professional development. The planners, speakers and authors of this CME activity have been encouraged to address issues relevant in their topic area. In addition, a variety of resources are available that address cultural and linguistic competency, some of which may be included in your syllabus or handout materials. Additional resources and information about AB1195 can be found on our website at <http://cme.ucsd.edu>.

Faculty List (as of October 7, 2011)

Course Directors

Paul S. Aisen, MD
 Alzheimer's Disease Cooperative Study (ADCS)
 Department of Neurosciences
 UCSD School of Medicine

Jacques Touchon, MD, PhD
 Chair of the Department of Neurology
 Montpellier University Hospital
 France

Bruno Vellas, MD, PhD
 Toulouse University Hospital
 Department of Neurology
 Toulouse, France

UC San Diego

M. Colin Ard, PhD
 Department of Neurosciences
 UCSD School of Medicine

Steven D. Edland, PhD
 Data Management and Statistics
 Department of Neurosciences
 UCSD School of Medicine

Douglas Galasko, MD
 Department of Neurosciences
 UCSD School of Medicine

Adam S. Fleisher, M.D., M.A.S. | Associate Professor, Department of Neurosciences University of California, San Diego, Associate Director of Brain Imaging Banner Alzheimer's Institute Medical Director, Alzheimer's Disease Cooperative Study

Dominic Holland
 Alzheimers Disease Neuroimaging Initiative
 UCSD School of Medicine

Visiting Faculty

Sandrine Andrieu, MD, PhD
 Toulouse University Hospital
 Department of Neurology
 Toulouse, FRANCE

Alireza Atri, M.D., Ph.D.
 Memory Disorders Unit
 Massachusetts General Hospital
 MIND BRAIN Laboratory
 Geriatric Research, Education and Clinical Center (GRECC)
 ENRM VA Bedford Medical Center
 Boston, MA, USA

Laura Baker, MD
 Assistant Professor of Psychiatry & Behavioral Sciences,
 University of Washington School of Medicine
 Seattle, WA
 USA

Jerome Barakos, MD
 California Pacific Medical Center
 San Francisco, CA
 USA

Karim Bennis, MD
 Department of Neurology
 Montpellier University Hospital
 Montpellier, France

Adam Boxer, MD
 University of California San Francisco
 San Francisco, CA
 USA

Andrew E. Busdon, MD
 Professor of Neurology
 Boston University
 Associate Director, ADC Research
 Boston VA Medical Center
 Boston, MA
 USA

Cynthia Carlsson, MD
 Department of Medicine
 University of Wisconsin
 Madison, WI
 United States
 Jeff Cummings, MD
 Cleveland Clinic Lou Ruvo Brain Institute
 Las Vegas, NV
 USA

Rachelle S. Doody, MD, PhD
 Effie Marie Cain Chair in Alzheimer's Disease Research
 Director, Alzheimer's Disease and Memory Disorders Center
 Baylor College of Medicine-Department of Neurology
 Houston, Texas USA

Bruno Dubois, MD, PhD
 Neurological Institute,
 University Salpêtrière Hospital
 Paris, France

Howard Feldman, MD
 Global Clinical Research, Neuroscience
 Bristol Myers Squibb
 New York, NY
 USA

Audrey Gabelle, MD
 Department of Neurology, Memory center,
 University Hospital Gui de Chauliac
 Montpellier
 FRANCE

Lidia Glodzik, MD
 Department of Psychiatry (Ctr of Brain Health)
 NYU Langone Medical Center
 New York, NY
 USA

Michael Gold, MD
 Allon Therapeutics
 Vancouver, BC
 Canada

Paula Grammas, MD
 Garrison Institute on Aging,
 Texas Tech University Health Science Center,
 Lubbock, TX
 USA

Suzanne Hendrix, PhD
 Pentara Corporation,
 Salt Lake City, UT
 USA

Edward Herskowitz, MD
 Department of Radiology,
 University of Pennsylvania,
 Philadelphia, PA.
 USA

William Hu, MD, PhD
 Alzheimer's Disease Research Center
 Emory University
 Atlanta, GA
 USA

Faculty List

Edward (Ted) Huey, MD
Departments of Psychiatry and Neurology
Columbia University
New York, NY
USA

Stella Karantzoulis, PhD
Center of Excellence on Brain Aging
New York University Langone Medical Center,
New York, NY
USA

Jeffrey Kaye, MD
Professor of Neurology and Biomedical Engineering
Director, NIA - Layton Aging & Alzheimer's Disease Center
Director, NIA - ORCATECH - Oregon Center for Aging & Technology
Oregon Health & Science University and Portland Veterans Affairs
Portland, Oregon USA

David Knopman, MD
Neurology
Mayo Clinic,
Rochester, MN
USA

Amos D. Korczyn, MD PhD
Sieratzki Chair of Neurology
Tel-Aviv University Medical School
Ramat Aviv, Israel

Joel Kramer, MD
Neurology
University of California, San Francisco
San Francisco, CA
USA

Richard Kryscio, MD
Sanders-Brown Center on Aging
University of Kentucky
Lexington, KY
USA

Jessica Langbaum, PhD
Banner Alzheimer's Institute
USA

Brian Lawlor, MD
St. James's Hospital,
Dublin, Ireland

Christopher Leisman, PharmD, MS
Janssen Alzheimer Immunotherapy
USA

Steven Leiser, PhD,
Lundbeck Research
USA

William R. Lenderking, PhD
Senior Research Scientist
Center for Health Outcomes Research
United BioSource Corporation
USA

José A. Luchsinger, MD MPH
Associate Professor of Medicine and Epidemiology
at New York Presbyterian Hospital/Columbia University Medical Center
Northern Manhattan Center of Excellence in Minority Health and Health
Disparities (NOCEMHD) at Columbia University
Division of General Medicine
New York, NY USA

Constantine G. Lyketsos, MD
Chair of Psychiatry, Johns Hopkins Bayview
Vice Chair of Psychiatry, Johns Hopkins Medicine
Baltimore, MD
USA

Ian Mackenzie, MD
University of British Columbia
Vancouver, BC
Canada

Rupert McShane, MD
Cochrane Dementia and Cognitive Improvement Group
University of Oxford
United Kingdom

David Miller, MD
Therapeutic Area
Bracket global Co.
USA

Anna Noel-Storr, MD
Cochrane Dementia and Cognitive Improvement Group
University of Oxford
United Kingdom

John Olichney, MD,
Neurology department
University of California Davis
USA

Pierre-Jean Ousset, MD
Centre Mémoire - Gérontopôle
Memory Clinic - Toulouse University Hospital
France

Oliver Peters, MD Department of Psychiatry,
Charité-CBF,
Berlin
GERMANY

Ronald C. Petersen, M.D., Ph.D.
Mayo Alzheimer's Disease Research Center
Mayo Clinic
Rochester, MN
USA

Anton P. Porsteinsson M.D.
William B. and Sheila Konar Professor of Psychiatry
Director, Alzheimer's Disease Care, Research and Education Program
(AD-CARE)
Director, Memory Disorders Clinic
University of Rochester School of Medicine
Rochester, N.Y.
USA

Terry Quinn, MD
Cochrane Dementia and Cognitive Improvement Group,
University of Glasgow
Glasgow, Scotland
United Kingdom

Jacob Raber, PhD
Oregon Health and Science University
Portland, Oregon USA

Nandini Raghavan, PhD
Johnson and Johnson Research
Raritan NJ,
USA

Ruth Remington, PhD
University of Massachusetts Lowell
Lowell, MA
USA



Faculty List

Matthias Riepe, MD, PhD
Department of Geriatrics and Psychiatry
University of Ulm
Günzburg, Germany

Howard Rosen, MD
Neurology
University of California San Francisco
San Francisco, CA
USA

Allen Roses, MD
Duke University School of Medicine
Durham, NC
United States

Stephen Salloway, M.D., M.S.
Director of Neurology and the Memory and Aging Program, Butler
Hospital
Professor of Clinical Neurosciences and Psychiatry
The Warren Alpert Medical School of Brown University
Providence, RI USA

Cristina Sampaio, MD, PhD
Laboratory of Clinical Pharmacology and Therapeutics,
Faculty of Medicine,
Lisbon,
Portugal

Mary Sano, PhD
Director, Alzheimer Disease Research Center
Professor, Department of Psychiatry
Mount Sinai School of Medicine
Director of Research and Development
James J Peters VAMC
Bronx NY, USA

Philip Scheltens, MD, PhD
Alzheimer Centrum en afd. Neurologie
VU Medisch Centrum
Amsterdam, The Netherlands

Achim Schneiderberger, MD, PhD
AFFIRIS AG
Vienna
AUSTRIA

Lon Schneider, MD,
Alzheimer's Disease Research and Clinical Center
Department of Psychiatry Geriatric Studies Center
University of Southern California
Los Angeles, CA
USA

Marta Segerdhal, MD, PhD
Medical Sciences
Research and Development
AstraZeneca
Sodertalje, Sweden

William R. Shankle, MS MD FACP
Shankle Clinic
Newport Beach, CA
Department of Cognitive Sciences,
UC Irvine, Irvine, CA, USA

Koichi Shudo, MD
Research Foundation
Itsuu Laboratory
Tokyo, Japan

Nadja Smailagic, MD
Cochrane Dementia and Cognitive Improvement Group,
University of Cambridge
Cambridge
United Kingdom

David Smith, MD
OPTIMA
University of Oxford
Oxford
United Kingdom

Reisa Sperling, M.D.
Associate Professor of Neurology, Harvard Medical School
Director, Center for Alzheimer Research and Treatment
Brigham and Women's Hospital
Massachusetts General Hospital
Boston, MA
USA

René Spiegel, MD
Memory Clinic,
Department of Geriatrics,
University Hospital
Basel, Switzerland

Joyce Suhy, MD
Synarc
USA

Pierre Tariot, MD,
Banner Alzheimer's Institute
Phoenix, AZ
USA

Christopher van Dyck, MD
Alzheimer's Disease Research Unit,
Yale University School of Medicine
New Haven, CT
USA

Diana Woodruff-Pak, PhD
Neuroscience Program and Psychology Department,
Temple University
Philadelphia, PA, USA

Disclosure summary (as of October 7, 2011)

It is the policy of the University of California, San Diego School of Medicine to ensure balance, independence, objectivity and scientific rigor. All persons involved in the selection, development and presentation of content are required to disclose any real or apparent conflicts of interest. All conflicts of interest will be resolved prior to an educational activity being delivered to learners through one of the following mechanisms 1) altering the financial relationship with the commercial interest, 2) altering the individual's control over CME content about the products or services of the commercial interest, and/or 3) validating the activity content through independent peer review. All persons are also required to disclose any discussions of off label/unapproved uses of drugs or devices. Persons who refuse or fail to disclose are disqualified from participating in the CME activity. Participants will be asked to evaluate whether the speaker's outside interests reflect a possible bias in the planning or presentation of the activity. This information is used to plan future activities.

Speaker Name	Name of Commercial Interest	Nature of Relevant Relationship Employee, Grants/Research Support recipient, Board Member, Advisor or Review Panel member, Consultant, Independent Contractor, Stock Shareholder (excluding mutual funds), Speakers' Bureau, Honorarium recipient, Royalty recipient, Holder of Intellectual Property Rights, or Other
Jerome Barakos	Synarc	Consultant
Adam Boxer	Allon therapeutics, BMS	Grant/contract, consultant
Jeffrey Cummings	<ul style="list-style-type: none"> - Abbott, Acadia, Acerra, ADAMAS, Anavex, Astellas, Avanir, Baxter, Bristol-Myers Squibb, Eisai, Elan, EnVivo, Forest, Genentech, GlaxoSmithKline, Janssen, Lilly, Lundbeck, Medivation, Medtronic, Merck, Merz, Neurokos, Novartis, Pfizer, Prana, QR, Sonexa, Takeda, and Toyama - Bayer, Avid, GE, MedAvante, Neurotrax, and UBC. - ADAMAS, Prana, Sonexa, MedAvante, Neurotrax, Neurokos, and QR pharma - Eisai, Forest, Janssen, Novartis, Pfizer, Lundbeck. - Neuropsychiatric Inventory - other 	Consultant for pharmaceutical companies Consultant for assessment companies Stockholder Speaker/lecturer Copyright owner Expert witness/legal consultation regarding olanzapine and ropinerol.
Rachelle Doody	Pfizer, UBC	<ul style="list-style-type: none"> - Baylor has contracts for two clinical trials for which I am PI. I provided one consultation to the company related to global drug development - Consultant on the development of patient reported outcomes
Bruno Dubois	Eisai	Consultant
Steven D. Edland	Eli Lilly	Data monitoring Board
Howard Feldman	BMS	Full-time employee
Adam Fleisher	Avid, Lilly	Partial grant funding for project presented Consultant
Steven C. Leiser	Lundbeck research	Employee
William Linderking	UBC	Employee

Disclosure summary

Speaker Name	Name of Commercial Interest	Nature of Relevant Relationship
Constantine Lyketsos	- Astra-Zeneca, GSK, Eisai, Novartis, Forest, Supernus, Adlyfe, Takeda, Wyeth, Lundbeck, Merz, Lilly, Pfizer, Genentech, Elan, NFL Players Association, NFL Benefits office - NIMH, NIA, Associated Jewish Federation of Baltimore, Weinberg Foundation, Forest, GSK, Eisai, Pfizer, Astra-Zeneca, Lilly, Ortho-McNeill, BMS, Novartis, National Football League, Elane	Grant support Consultant
David Miller	Bracket (part of UBC)	Full-time employee
Anton P. Porsteinsson, MD	Baxter, BMS, Elan, Genentech/Roche, Janssen Alzheimer Initiative, Medivation, Pfizer, Toyama Elan, Janssen Alzheimer Initiative, Medivation, Pfizer, Transition Therapeutics Forest	Grant/Research Support Consultant/Advisory Board Speakers' Bureau
Nandini Raghavan	Johnson and Johnson	Employee and shareholder
Matthias Riepe	Eisai, Elan, Janssen, Lundbeck, Merz, Novartis, Pfizer, Wyeth	Grants/honoraria for dementia-related work
Allen David Roses	Eli Lilly, Takeda Pharma, Zinfandel	Consultant, consultant, Owner
Lon S. Schneider	Pfizer, Novartis Johnson and Johnson	Research support Consultant
Märta Segerdhal	AstraZeneca	Employee
William R. Shankle	Medical Care Corporation	Employee, Board Member, Stock Shareholder
Reisa Spierling	Pfizer, BMS, Roche, Janssen, Eisai	Consultant
Pierre Tariot	Acadia, AC Immune, Allergan, Eisai, Inc., Genentech, Medavante, Novartis, sanofi aventis, Schering-Plough, Abbott Laboratories, AstraZeneca, Avid, Bristol Myers Squibb, Élan, GlaxoSmithKline, Eli Lilly, Medivation, Merck and Company, Pfizer Inc., and Wyeth Laboratories	Consultant
Christopher H. van Dyck	- Bristol-Myers Squibb, Pfizer Inc, Janssen AI, Elan Pharmaceuticals, GlaxoSmithKline - Eli Lilly, Baxter Pharmaceuticals, Medivation, Genentech	Consultant/Scientific Advisory Grants/Research Support

The following have no relevant financial relationships to disclose :

Paul Aisen, Sandrine Andrieu, Colin Ard, Laura Baker, Jerome Barakos, Karim Bennys, Andrew Budson, Maria Carillo, Cynthia Carlsson, Audrey Gabelle, Lidia Glodzik, Suzanne Hendrix, Edward Herskovits, Dominic Holland, Stella Karantzoulis, Zaven Khachaturian, Jeffrey Kaye, David Knopman, Richard Kryscio, Jessica Langbaum, Brian Lawlor, Christopher Leitman, Jose Luchsinger, Ian Mackenzie, Rupert McShane, Anna Noel-Storr, John Olichney, Pierre-Jean Ousset, Oliver Peters, Terry Quinn, Jacob Raber, Ruth Remington, Philip Scheltens, Lon Schneider, Koichi Shudo, Nadja Smailagic, A. David Smith, René Spiegel, Joyce Suhy, Jacques Touchon, Bruno Vellas, Diana Woodruff-Pak.

The CME staff, meeting planners, planning committee and CME committee reviewers do not have any relevant financial relationships to disclose.

This educational activity may contain discussion of unlabeled and/or investigational uses of agents that are not approved by the FDA. Please consult the prescribing information for each product. The views and opinions expressed in this activity are those of the faculty and do not necessarily reflect the views of the University of California, San Diego.

Clinical Trials on Alzheimer's Disease (CTAD) would like to thank the following companies for their ongoing support helping CTAD meet its mission and goals.



Bristol-Myers Squibb



**ALZHEIMER'S
IMMUNOTHERAPY PROGRAM**
INNOVATION TO REMEMBER™



CTAD 2012

Clinical Trials on Alzheimer's Disease

Las Vegas '09 | Toulouse '10 | San Diego '11 | Monte Carlo '12

Clinical Trials on Alzheimer's Disease

October 29-31, 2012
Monte Carlo

Clinical Trials

<http://www.ctad.fr>



**CTAD
Monte Carlo
2012**



European Alzheimer's Disease Consortium
Montpellier and Toulouse EADC Centers



ASSOCIATION MONÉGASQUE
POUR LA RECHERCHE SUR LA
MALADIE D'ALZHEIMER
AMPA



UC San Diego
SCHOOL OF MEDICINE